argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
ADAPT OCULUS is the first study to evaluate a targeted treatment for…
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
February 22, 2026 16:00 ET | Source: Dyne Therapeutics, Inc. - Late-breaking…


